,
5 min read
Software is no longer an accessory in healthcare it is increasingly central to diagnosis, monitoring, decision support, and treatment planning. In India, this shift has prompted regulators to clarify how Software as a Medical Device (SaMD) should be governed under existing laws that were originally designed for traditional medical devices. Understanding SaMD regulation in India is not just about compliance; it’s about aligning product strategy with a rapidly evolving digital health ecosystem that includes artificial intelligence, cloud deployment, and real-world performance expectations.
India’s approach to SaMD has been shaped by the Medical Devices Rules, 2017, which brought medical software within the scope of the Central Drugs Standard Control Organisation (CDSCO) and State Licensing Authorities. This regulatory framework is now being refined to address software-specific questions around classification, licensing, quality management, and lifecycle governance at a time when artificial intelligence and machine learning in software as a medical device are becoming commonplace in clinical practice.
Understanding SaMD Under the Indian Regulatory Framework
In India, the Central Drugs Standard Control Organisation (CDSCO) is the apex body responsible for regulating medical devices, including SaMD. Its role is similar to that of the US FDA or the European Union for their respective markets. CDSCO interprets and applies the Medical Devices Rules, 2017 to determine whether a software falls under medical device regulation and what compliance requirements it must meet.
Medical software that performs one or more medical purposes such as diagnosis, monitoring, prevention, or treatment without being part of a hardware medical device is typically treated as SaMD. Standalone clinical decision support tools, AI-enabled image analysis, and software that synthesizes or interprets patient data are all examples of products that may qualify.
The CDSCO’s 2025 Guidance provides a formal framework for this classification, aligning India with IMDRF standards. It introduces a risk-based approach (Class A to D) centered on the software's clinical impact and the seriousness of the underlying condition. Crucially, the guidance establishes an Algorithm Change Protocol (ACP) for AI/ML-based tools, allowing for iterative updates without constant re-licensing. By clarifying these pathways and emphasizing cybersecurity, the CDSCO ensures that digital health innovations can scale while maintaining rigorous safety and performance standards within the Indian ecosystem.
Risk-Based Classification: SaMD Classification in India
A foundational aspect of SaMD regulation in India is risk-based classification, which mirrors global norms in proportioning regulatory attention to clinical risk. The four classes are:
- Class A (Low Risk): Low‐impact products such as retrospective data analysis tools.
- Class B (Low-Moderate Risk): Products with some effect on clinical decisions, but limited potential for harm.
- Class C (Moderate-High Risk): Software that plays a significant role in diagnosis or therapy decisions.
- Class D (High Risk): Products with potential for serious health consequences if they fail.
This structure reflects the same risk tiers used for general medical devices and aims to ensure that higher-impact SaMD products face commensurate scrutiny. In practice, classification is based on both intended use and the severity of outcomes if the software behaves incorrectly a principle that underscores the importance of careful risk assessment early in product development.
This risk-based lens also aligns India’s system with globally recognized approaches, such as those codified by the International Medical Device Regulators Forum (IMDRF) and used in jurisdictions like the United States and Europe.
Regulatory Submissions & SaMD Registration Process in India
Once classification is determined, companies must navigate the SaMD registration process in India to market their software legitimately. Under the MDR, licensing requirements vary by class:
- Class A and Class B SaMD: Licenses are issued by State Licensing Authorities (SLAs).
- Class C and Class D SaMD: The CDSCO centrally issues these licenses.
- Imported SaMD: Requires an import license from CDSCO before entry into the Indian market.
Applications are typically submitted through CDSCO’s online portals, which consolidate documentation, product details, QMS evidence, and other required artifacts. For higher-risk classes, technical documentation including architectural descriptions, intended use statements, risk management plans, clinical performance summaries, and evidence of quality controls must be comprehensive and aligned with lifecycle expectations.
It’s worth noting that CDSCO has released draft guidance on Medical Device Software to provide more structured interpretive clarity on submission routes, documentation expectations, lifecycle obligations, and definitions for medical device software though this draft clarifies rather than creates new statutory requirements.
SaMD Approval Process India & Quality Expectations
For approval under SaMD regulation in India, regulatory submissions must demonstrate not only baseline safety and performance but also robust quality practices and lifecycle governance. This means:
- Articulating clear intended use and risk context
- Maintaining a risk-based quality management system
- Demonstrating clinical relevance or performance in the intended population
- Documenting rigorous software validation, including verification and testing processes
- Planning for post-market surveillance and updates
While India’s Medical Devices Rules do not currently provide as detailed an algorithm change protocol as some counterpart systems, the draft guidance on medical device software signals a willingness to adopt lifecycle-oriented structures that encompass cybersecurity, cloud deployment, and updates especially for software with adaptive behaviour.
This regulatory stance reflects broader trends in digital health regulation in India, where the National Digital Health Mission (NDHM) and related initiatives are promoting interoperability, data standards, and secure information exchange across healthcare systems. The policy environment is therefore shifting from ambiguity to structured oversight making regulatory planning a strategic consideration rather than a compliance afterthought.
Emerging Considerations for AI/ML-Enabled SaMD
As artificial intelligence and machine learning in software as a medical device become embedded in clinical workflows, regulators are paying closer attention to documentation, change management, real-world performance monitoring, and bias mitigation. Although India’s MDR and CDSCO draft guidance do not yet provide specific AI/ML-centric regulations, the broad emphasis on technical documentation and risk-based classification means that developers of AI-enabled systems must be prepared to explain datasets, validation methods, and algorithmic logic as part of their regulatory submissions.
This expectation mirrors global movements toward AI transparency and lifecycle validation, such as guidance emerging from the FDA and IMDRF for AI/ML-based software systems suggesting that India’s regulatory architecture will continue to evolve in step with international norms.
Strategic Implications & Emerging Market Dynamics
Understanding SaMD India regulatory compliance is essential not just for regulatory approval, but also for broader market strategy. The regulatory environment is maturing at a time when India’s healthcare ecosystem is embracing digital diagnostics, telemedicine integrations, and data-driven care coordination. Developers and innovators should therefore treat regulatory clarity as a competitive asset integrating compliance into product strategy rather than postponing it to the final stages.
With CDSCO’s draft guidance nearing finalization and with greater clarity on classification, lifecycle obligations, and submission expectations, global and domestic companies are now better positioned to navigate India’s SaMD regime. In practice, teams that approach lifecycle oversight as a structured governance discipline rather than a reactive compliance exercise tend to align more effectively with the expectations outlined in Comprehensive Guide to Software as a Medical Device (SaMD) Compliance & Global Registration and operational frameworks reflected in Software as a Medical Device (SaMD) Regulatory Compliance.
Contact Freyr Solutions to discuss your SaMD Regulatory strategy and discover how Freyr can streamline your global registrations.
